Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy.

World journal of methodology·2025
Same author

Usage Pattern of Fixed-dose Combinations at ICMR Network of Rational Use of Medicine Centres across India: Recommendations for Policymakers and Prescribers.

The Journal of the Association of Physicians of India·2023
Same author

Price Dispersion of Vitamin D Supplements Over Time: An Initiative for Prescriber Education.

Indian journal of endocrinology and metabolism·2021
Same author

Spaced education and student learning: Results from a medical school.

The clinical teacher·2020
Same author

Critical Issues and Recent Advances in Anticoagulant Therapy: A Review.

Neurology India·2019
Same author

Pediatric Off-Label and Unlicensed Drug Use and Its Implications.

Current clinical pharmacology·2017

Related Experiment Video

Updated: May 13, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Belimumab: targeted therapy for lupus.

Preeta K Chugh1, Bhupinder S Kalra

  • 1Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India. docpreeta@yahoo.com

International Journal of Rheumatic Diseases
|February 28, 2013
PubMed
Summary

Belimumab, a new biologic therapy for systemic lupus erythematosus (SLE), effectively treats active disease in patients with autoantibodies. Clinical trials show it is well-tolerated and offers a promising alternative to traditional treatments.

More Related Videos

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 13, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Area of Science:

  • Immunology and Rheumatology
  • Pharmacology and Therapeutics

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystemic effects, characterized by unpredictable flares and remissions.
  • Current SLE management relies on corticosteroids, antimalarials, and immunosuppressants, often associated with significant side effects.
  • Belimumab, a B-lymphocyte stimulator (BLyS) inhibitor, represents a novel targeted therapy for SLE.

Purpose of the Study:

  • To review the role of belimumab in treating systemic lupus erythematosus (SLE).
  • To discuss the clinical trials that led to the FDA approval of belimumab for SLE.
  • To evaluate belimumab's efficacy and safety in active SLE patients.

Main Methods:

  • Review of randomized, double-blind, phase III clinical trials (BLISS-52 and BLISS-76).
  • Assessment of patient response using the SLE Responder Index (SRI).
  • Evaluation of treatment tolerability and safety profiles.

Main Results:

  • Belimumab demonstrated significant efficacy in patients with autoantibody-positive active SLE on stable background therapy.
  • A significantly greater response rate was observed with belimumab compared to placebo in the BLISS trials.
  • Belimumab was generally well-tolerated in the studied patient population.

Conclusions:

  • Belimumab offers a targeted approach to SLE management by inhibiting BLyS, a key factor in B-cell pathogenesis.
  • This biologic therapy shows promise in improving disease control and potentially altering the long-term course of SLE.
  • Further research is needed to assess belimumab's long-term safety and efficacy in diverse patient populations.